Scaling Up How Weight Loss Drugs Propel HeliosX Towards the Billion Pound Club

HeliosX, the London-based online pharmacy, has made significant strides in the weight-loss drug market, recently boasting a remarkable reduction of 8.5 million kilograms in patient weight, equating to approximately 3.5 Olympic-sized swimming pools worth of fat. Established in 2013, the company revealed an impressive profit of £30 million last year, calculated as earnings before interest, tax, and accounting items, from a customer base of 2.3 million. Sales surged from £178 million to £781 million, marking a substantial increase from £13 million recorded five years earlier.

This growth trajectory positions HeliosX to potentially breach the £1 billion milestone this year, aligning it with FTSE 250 retailers like AO World. Notably, the firm achieved this growth without reliance on venture capital, primarily funded through its cash flow. Dwayne D’Souza, the founder, is set to benefit significantly, owning over 90 percent of the shares while employing the remainder of the workforce.

As Tim Cockroft, executive chairman of Singer Capital Markets, highlights, it is uncommon for an owner-funded business to rapidly grow and remain profitable. Just two years ago, D’Souza led a relatively stable business with 51 employees; it now employs 1,119, alongside establishing a US digital pharmacy operation in Florida and expanding into Germany and Canada.

The onset of the Covid-19 pandemic played a pivotal role in HeliosX’s expansion, with D’Souza seizing opportunities presented by the closure of physical shops. Among the key hires was Stuart Peak, who transitioned to chief executive in 2024, demonstrating a commitment to strategic growth. Peak’s healthcare background, including time at PwC and work with Swiss healthcare business Oviva, has equipped him for the challenges faced.

Initially focused on utilising limited capital to grow, the company has since shifted toward managing the complexities of hyper-growth while investing in infrastructure. The decision to shift distribution from east London to a larger site in Leamington Spa has proven vital; within nine months, four million orders were processed from the new location.

Despite achieving remarkable sales growth, operational challenges persist. Approximately 99 percent of HeliosX’s offerings comprise regulated prescription drugs. Compliance with Advertising Standards Authority rules, as well as requirements from the Care Quality Commission and General Pharmaceutical Council, remains critical. Peak acknowledges previous mistakes but emphasises a commitment to patient safety and clinical standards as they navigate a rapidly developing sector.

The regulatory landscape continues to evolve, particularly concerning marketing practices. Recently, the ASA clamped down on social media promotions that violated advertising guidelines. HeliosX has adapted its marketing strategies to comply with these new regulations, thus preserving its operational integrity and reputation.

Demand for weight loss medications remains strong, even following price increases. Peak believes the UK market has not yet reached peak usage and anticipates continued growth as new medications enter the market. While the company currently has no immediate plans for a trade sale or public offering, strategic acquisitions are under consideration to further enhance its market position.